Preoperative Systemic Immune-Inflammation Index (SII) for Predicting the Survival of Patients with Stage I-III Gastric Cancer with a Signet-Ring Cell (SRC) Component

Table 1

Characteristics of 512 patients with gastric cancer with an SRC component.

Variables	Value (%)
Sex
Men	332 (64.8)
Women	180 (35.2)
Age (years)
<55	246 (48.0)
≥55	266 (52.0)
SRCC
pSRCC	68 (13.3)
mSRCC	444 (86.7)
Chemotherapy
Yes	244 (47.7)
No	268 (52.3)
Tumor size(cm)
<4.75	228 (44.5)
≥4.75	284 (55.5)
pT
T1	84 (16.4)
T2	64 (12.5)
T3	62 (12.1)
T4	302 (59.0)
pN
N0	166 (32.4)
N1	86 (16.8)
N2	100 (19.5)
N3a	102 (19.9)
N3b	58 (11.4)
pTNM
I+II	220 (43.0)
III	292 (57.0)
Tumor location
Lower stomach	328 (64.1)
Middle stomach	75 (14.6)
Upper stomach	35 (6.8)
LM stomach	53 (10.3)
MU stomach	7 (1.4)
LMU stomach	14 (2.8)
Leukocyte
<6.17	292 (57.0)
≥6.17	220 (43.0)
Neutrophil
<3.27	260 (50.8)
≥3.27	252 (49.2)
Hemoglobin
<121.2	140 (27.3)
≥121.2	372 (72.7)
Fibrinogen
<3.06	268 (52.3)
≥3.06	244 (47.7)
Prealbumin
<234.5	247 (48.2)
≥234.5	265 (51.8)
Albumin
<42.5	292 (57.0)
≥42.5	220 (43.0)
Globulin
<29.9	425 (83.0)
≥29.9	87 (17.0)
SII
<527	340 (66.4)
≥527	172 (33.6)
PNI
<48.73	176 (34.4)
≥48.73	336 (65.6)
Total gastrectomy
Yes	113 (22.1)
No	399 (77.9)
NLR
<2.2	340 (66.4)
≥2.2	172 (33.6)

SRC: signet-ring cell; SRCC: signet-ring cell carcinoma; pSRCC: pure signet-ring cell cancer; mSRCC: mixed signet-ring cell cancer; LM: lower and middle; MU: middle and upper; LMU: lower, middle, and upper; SII: systemic immune-inflammation index; PNI: prognostic nutritional index; NLR: lymphocyte to neutrophil ratio.